Patients with thoracic cancer and COVID-19 had a high mortality rate and were frequently not offered intensive care in the global TERAVOLT registry.
A ctDNA test identified patients who would develop early relapse after surgical resection of stage I to III NSCLC.
A test using plasma cfDNA detected cancer in patients who were suspected to have cancer, and was able to predict tissue of origin among patients with confirmed cancer.
A multicancer liquid biopsy test identified multiple cancer types in older women with no history of cancer, according to a prospective study of nearly 10,000 women.
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
Racial and ethnic disparities have emerged among patients with cancer and COVID-19, with black and Hispanic populations experiencing disproportionality high mortality rates.
Patients with cancer did not demonstrate a more aggressive or lethal COVID-19 disease course in a French population.
Patients with cancer who contracted COVID-19 demonstrated an aggressive presentation and poor outcomes, according to a retrospective study from Wuhan.
An institution in Italy has adapted their cancer care model to minimize the risk to patients and health care workers, while still prioritizing patients with cancer.
Pneumonitis occurred more frequently among patients with NSCLC and a prior history of noninfectious pneumonitis, and with immune checkpoint inhibitors compared with chemotherapy.
Atezolizumab plus enzalutamide failed to improve OS compared with enzalutamide alone among patients with mCRPC in the IMbassador250 trial.
Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.
Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.
The presenter said “there may be promising activity with olaparib and durvalumab in addition to paclitaxel” in this breast cancer subtype.